{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/delirium/prescribing-information/haloperidol/","result":{"pageContext":{"chapter":{"id":"fa09afb1-cc68-5f68-afbe-7486c91a5ed4","slug":"haloperidol","fullItemName":"Haloperidol","depth":2,"htmlHeader":"<!-- begin field 44ba2180-91f5-4bf5-9046-9089da8e5c36 --><h2>Haloperidol</h2><!-- end field 44ba2180-91f5-4bf5-9046-9089da8e5c36 -->","summary":"","htmlStringContent":"<!-- begin item 025ec119-1a73-432a-ad9b-3e469ff1376e --><!-- begin field b7fb26d6-7ef9-4433-8155-6cf50ff9f340 --><div>Haloperidol (off-label indication) should only be used for the treatment of challenging behaviour associated with delirium on the advice of a specialist.</div><!-- end field b7fb26d6-7ef9-4433-8155-6cf50ff9f340 --><!-- end item 025ec119-1a73-432a-ad9b-3e469ff1376e -->","topic":{"id":"6b89f111-d1d1-510e-8846-71e15c389f06","topicId":"64430de8-33e7-409d-b433-725a712a6f41","topicName":"Delirium","slug":"delirium","lastRevised":"Last revised in April 2020","chapters":[{"id":"0455d257-6ef6-5e50-9dc0-21780666b8e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a71db69b-5a97-544a-a806-ec82704f3907","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"58e84228-4844-5721-859b-91d58faa7eb6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"999affe9-788e-52a9-83c8-ad933103eeb5","slug":"changes","fullItemName":"Changes"},{"id":"29c67640-566b-5fa4-8966-5b08ca667756","slug":"update","fullItemName":"Update"}]},{"id":"6dddaa0e-c24c-5f4e-8044-6a3229f859df","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7e8bf385-fd9a-544a-bc9d-375555c17ab0","slug":"goals","fullItemName":"Goals"},{"id":"8f18311c-4fad-5969-8a94-addcca05fb64","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b45b0c3d-03c0-5300-b0c4-62ccd106e229","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7b7d4906-4705-52ba-a39f-ecfb7c5d1e98","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"331ceb18-88fc-530e-aa48-bae28dde9901","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"558ba6d3-06ab-5370-b6b7-09548f2c3c8e","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"b6e24e45-958a-5052-800a-ef5c6f140719","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2b925b35-d493-5d01-bb58-9f18c37e1357","slug":"definition","fullItemName":"Definition"},{"id":"27bd26a5-66e1-5d51-a992-7e06e6a3cdfa","slug":"predisposing-factors","fullItemName":"Predisposing factors"},{"id":"c3582ffa-e505-5580-a3fa-f6a04f0938cc","slug":"precipitating-factors","fullItemName":"Precipitating factors"},{"id":"44402d85-ef9c-562b-ad2c-e99c0d8c60a7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"799dcaa5-4683-5bf0-a9d7-dfc860ab7c81","slug":"complications","fullItemName":"Complications"},{"id":"ca4b25bd-2486-55a7-92c0-c39322caa272","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"993580f3-4201-5dd5-8a6d-f64de509d328","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3f7d0746-b45f-5f52-8e49-7effac5e3547","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"f84af6b7-85fc-56aa-9554-29d1231a7fd1","slug":"assessment","fullItemName":"Assessment"},{"id":"cc3618cd-d41e-5719-939a-78ed0be305e4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9d04a09f-9612-570d-aeb7-c0121bda09c4","fullItemName":"Management","slug":"management","subChapters":[{"id":"81f2aa66-ed46-54f0-80b5-4dfca4afb344","slug":"management","fullItemName":"Scenario: Management"},{"id":"58bb812f-7b3c-57be-aab1-8ae228aff1d1","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"769a3265-9e21-5508-b937-bf6aa4a8f378","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"fa09afb1-cc68-5f68-afbe-7486c91a5ed4","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"4faac93d-8b62-5294-933f-214a1155f283","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"c02516c6-89cb-5dc3-99db-17f261f5f80e","slug":"levomepromazine","fullItemName":"Levomepromazine"}]},{"id":"cd438911-3d3a-51dd-8455-3e41c260dd60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cec2028c-5183-50fb-9bb7-f20aea64a152","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a5323429-af72-5d8b-a251-0715c1a15bba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"26c6273a-60c7-5b9a-b49f-9f9fbb623941","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b70aed75-14ce-57f4-b2b0-474fa4480d56","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c5faba8c-4118-59d9-af20-8c8d52a89eb2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"71e02a81-885f-515f-8852-109bc9b5580f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"51d66a08-1fc6-5593-8764-c9d4e547d827","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"769a3265-9e21-5508-b937-bf6aa4a8f378","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"3920e2a9-e30d-5ec0-b1de-62e7a4782581","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field 0c013219-ece0-4902-b33e-6489ceac804c --><h3>What dose of haloperidol should I prescribe and what monitoring is required?</h3><!-- end field 0c013219-ece0-4902-b33e-6489ceac804c -->","summary":"","htmlStringContent":"<!-- begin item b953ebde-6af4-4871-91de-a53ef99abffb --><!-- begin field 6e9a68c3-af07-4661-9e98-1c72e7c154c7 --><ul><li><strong>The use of haloperidol for the treatment of delirium is off-label</strong> — informed consent should be obtained and documented [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">NHS Evidence, 2012</a>].<ul><li>An ECG is recommended before initiation of haloperidol, particularly if cardiovascular risk factors, or a history of cardiovascular disease are present. ECG and blood pressure monitoring during treatment with haloperidol is advised.</li><li>Start at the lowest possible dose (0.25–0.5 mg) orally and titrate in increments if necessary after an interval of two hours until there is a clinical response [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Royal College of Physicians and British Geriatrics Society, 2006b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Inouye, 2014</a>]. <ul><li>Note that this dose is lower than that stated in the BNF which gives the dose for the indication of agitation and restlessness in the elderly, as initially 0.75–1.5 mg orally, 2–3 times a day adjusted according to response [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>].</li></ul></li><li>As a general guide, the maximum dose in 24 hours (dependant on the severity of the person's symptoms, their weight, and sex) should not exceed 2 mg [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Healthcare Improvement Scotland, 2014</a>].</li></ul></li><li><strong>End of life care dosing</strong><ul><li>Prescribe 1.5mg subcutaneously (SC) once or twice daily. Review within 24 hours. If symptoms are controlled, continue SC either as stat doses 12-24 hourly or via syringe driver.  If symptoms are not controlled, increase to 5mg/24 hours SC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Northern&nbsp;England Clinical&nbsp;Networks, 2016</a>].</li></ul></li><li><strong>One-to-one care of the person</strong> should be available while the dose is titrated in a controlled and safe manner [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Royal College of Physicians and British Geriatrics Society, 2006b</a>].</li><li><strong>Review the person regularly</strong> and discontinue haloperidol as soon as possible — aim to reduce and stop haloperidol after 24–48 hours [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Royal College of Physicians and British Geriatrics Society, 2006b</a>].</li></ul><!-- end field 6e9a68c3-af07-4661-9e98-1c72e7c154c7 --><!-- end item b953ebde-6af4-4871-91de-a53ef99abffb -->","subChapters":[]},{"id":"6fb00ccd-9d94-5bf7-8454-5c2ee763b936","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7e4d965b-de68-4063-b88f-6174c8e4e0c2 --><h3>What are the possible adverse effects of haloperidol?</h3><!-- end field 7e4d965b-de68-4063-b88f-6174c8e4e0c2 -->","summary":"","htmlStringContent":"<!-- begin item d9eef26f-a067-49e4-baef-335aea2a0e71 --><!-- begin field 06628b84-0761-45d7-930c-490b97e4115f --><ul><li><strong>Extrapyramidal symptoms </strong>(such as Parkinsonism, dystonic reactions, and akathisia). Acute dystonias may occur early in treatment and irreversible tardive dyskinesia may develop during treatment or after the drug has been discontinued.</li><li><strong>Cardiac effects</strong><ul><li>Dose-related hypotension can occur, particularly in elderly people, and may lead to falls.</li><li>QT interval prolongation — cases of sudden death have occurred.</li></ul></li><li><strong>Neuroleptic malignant syndrome</strong> — a rare but life-threatening adverse effect that can occur with any antipsychotic.<ul><li>Symptoms include hyperthermia, muscle rigidity, autonomic instability, and fluctuating consciousness.</li><li>Mortality without treatment is 20%; emergency medical treatment is needed.</li></ul></li><li><strong>Hormonal effects</strong> — these include hyperprolactinaemia, which may cause galactorrhoea and gynaecomastia. Very rare cases of hypoglycaemia and syndrome of inappropriate antidiuresis (SIAD) have been reported.</li><li><strong>Gastrointestinal effects</strong> — dry mouth, constipation, nausea, vomiting, loss of appetite, weight changes, and dyspepsia.</li><li><strong>Psychiatric effects </strong>— agitation, insomnia, and depression.</li><li><strong>Convulsions</strong> — seizures (the higher the dose, the greater the risk). </li><li><strong>Urinary retention</strong>.</li><li><strong>Visual disturbance </strong>— blurred vision and very rarely, precipitation of angle-closure glaucoma.</li><li><strong>Venous thromboembolism</strong> — cases of pulmonary embolism and deep vein thrombosis.</li><li><strong>Other adverse effects include</strong>: drowsiness; apathy; dizziness; headache; confusion; dyspnoea, bronchospasm, and laryngeal oedema; hypoglycaemia; hypertension; sweating; nasal congestion; blood dyscrasias (such as agranulocytosis and leucopenia); Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitization, contact sensitization and rashes; abnormal liver function tests and jaundice (including cholestatic); corneal and lens opacities; and purplish pigmentation of the skin, cornea, conjunctiva, and retina.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>]</p><!-- end field 06628b84-0761-45d7-930c-490b97e4115f --><!-- end item d9eef26f-a067-49e4-baef-335aea2a0e71 -->","subChapters":[]},{"id":"4d581cda-b098-5567-821b-9ee27a380c8b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 3d17ce7b-0f55-428f-9eef-99d0b5699e03 --><h3>What are the contraindications and cautions with haloperidol?</h3><!-- end field 3d17ce7b-0f55-428f-9eef-99d0b5699e03 -->","summary":"","htmlStringContent":"<!-- begin item 3ced6df3-9cc3-48db-ba69-6aef984462d8 --><!-- begin field ceb02168-dd02-4bfc-90f5-4b018cec6778 --><ul><li><strong>Do not prescribe haloperidol if the person has or is suspected of having:</strong><ul><li>Parkinson's disease, lesions of the basal ganglia, or Lewy-body dementia.</li><li>Central nervous system depression or neuromuscular weakness (such as myasthenia gravis) or they are in a comatose state.</li><li>A phaeochromocytoma.</li><li>A cardiac disorder, such as:<ul><li>QT interval prolongation or the person is taking other drugs that prolong the QT interval (such as antiarrhythmics, tricyclic antidepressants, erythromycin) or hypokalaemia (diuretics), or increase haloperidol levels (ketoconazole, itraconazole).</li><li>Recent acute myocardial infarction.</li><li>Uncompensated heart failure or second- or third-degree heart block.</li><li>Arrhythmias treated with class IA antiarrhythmic drugs (for example disopyramide, procainamide, quinidine) or class III antiarrhythmic drugs (for example amiodarone, sotalol), or a history of ventricular arrhythmia or Torsades de pointes.</li><li>Bradycardia.</li></ul></li><li>Uncorrected hypokalaemia — can increase the risk of cardiac arrhythmias.</li><li>Known hypersensitivity to haloperidol. </li></ul></li><li><strong>Haloperidol should be avoided where possible in the following groups of people. If the use of haloperidol cannot be avoided, close monitoring for <a class=\"topic-reference internal-reference\" href=\"/topics/delirium/prescribing-information/haloperidol/#adverse-effects\">adverse effects</a> is required.</strong><ul><li>Epilepsy (and conditions predisposing to seizures such as alcohol withdrawal and brain damage).</li><li>Depression.</li><li>Subarachnoid haemorrhage.</li><li>Prostatic hypertrophy.</li><li>Susceptibility to angle-closure glaucoma. </li><li>Severe respiratory disease.</li><li>Hepatic impairment or a history of jaundice.</li><li>Renal impairment.</li><li>Blood dyscrasias.</li><li>Metabolic disturbances such as hypokalaemia, hypocalcaemia, or hypomagnesaemia.</li><li>Hyperthyroidism.</li><li>Arteriosclerosis. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>]</p><!-- end field ceb02168-dd02-4bfc-90f5-4b018cec6778 --><!-- end item 3ced6df3-9cc3-48db-ba69-6aef984462d8 -->","subChapters":[]},{"id":"fb07cf37-52b5-5018-ad40-75c92e4e0f16","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field bc3155de-6b7b-4ea4-ade8-6524ddbbb7ed --><h3>What are the possible drug interactions with haloperidol?</h3><!-- end field bc3155de-6b7b-4ea4-ade8-6524ddbbb7ed -->","summary":"","htmlStringContent":"<!-- begin item 4c8fb9d0-3321-42f0-9eec-9d8618e72e90 --><!-- begin field 6847f571-73e3-4f23-9430-b51081a89ec6 --><p><strong>Haloperidol may interact with:</strong></p><ul><li><strong>Drugs known to prolong the QT interval</strong> (for example, anti-arrhythmics [such as amiodarone, and sotalol], certain antimicrobials [such as erythromycin], antidepressants such as amitriptyline, citalopram, and escitalopram, other neuroleptics [such as phenothiazines and sertindole], certain antihistamines [such as terfenadine], and mefloquine) — may increase the risk of ventricular arrhythmias, including Torsade de pointes. Avoid concomitant use.<ul><li>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment has been stopped.</li><li>Co-administration of citalopram and escitalopram with drugs that prolong the QT interval (such as antipsychotics including haloperidol) is contraindicated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">MHRA, 2011</a>].</li></ul></li><li><strong>Drugs causing electrolyte imbalance</strong> may increase the risk of ventricular arrhythmias and concomitant use should be avoided.<ul><li>In particular, diuretics causing hypokalaemia should be avoided. If necessary, potassium-sparing diuretics are preferred.</li></ul></li><li><strong>Drugs that inhibit the glucuronidation or cytochrome P450 enzyme system or those that decrease CYP 2D6 enzyme activity</strong> (for example itraconazole, quinidine, fluvoxamine, fluoxetine, sertraline, paroxetine, chlorpromazine, and promethazine) may result in increased haloperidol concentrations and an increased risk of adverse events, including QT-prolongation.</li><li><strong>Enzyme-inducing drugs</strong> (such as carbamazepine, phenobarbital, and rifampicin) can cause a significant reduction in plasma levels of haloperidol.</li><li><strong>Drugs that depress the central nervous system (CNS)</strong> (such as alcohol, hypnotics, sedatives, or strong analgesics) — concomitant use of haloperidol can increase CNS depression.</li><li><strong>Sympathomimetic drugs</strong> — haloperidol may antagonize the action of adrenaline and other sympathomimetic agents.</li><li><strong>Antidepressants:</strong><ul><li>Haloperidol inhibits the metabolism of tricyclic antidepressants and increases their plasma levels — avoid concomitant use.</li></ul><strong>Anticoagulant drugs </strong>— antagonism of the effect of phenindione has been reported. </li><li><strong>Antibiotic drugs</strong> — increased risk of ventricular arrhythmias when haloperidol given with moxifloxacin —avoid concomitant use.</li><li><strong>Antimalarial drugs </strong>— increased risk of ventricular arrhythmias when haloperidol given with mefloquine or quinine —avoid concomitant use.</li><li><strong>Anticonvulsant drugs </strong>— dosage of anti-convulsants may need to be increased to compensate for the lowered seizure threshold associated with haloperidol use.</li><li><strong>Lithium</strong> — in rare cases, an encephalopathy-like syndrome has been reported in people taking a combination of lithium and haloperidol. There is an increased risk of extrapyramidal adverse effects and potential neurotoxicity when haloperidol is given with lithium.</li><li><strong>Antiretroviral drugs</strong> — increased risk of ventricular arrhythmias when haloperidol given with saquinavir — avoid concomitant use.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>]</p><!-- end field 6847f571-73e3-4f23-9430-b51081a89ec6 --><!-- end item 4c8fb9d0-3321-42f0-9eec-9d8618e72e90 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}